OclacitinibMaleate

‌Oclacitinib Maleate | USP/EP-Certified JAK1 Inhibitor | Bulk API for Veterinary Dermatology‌
‌Google Keywords‌: Oclacitinib Maleate bulk supplier, JAK1 inhibitor API, pet allergy treatment, USP-certified veterinary drug

🌟 ‌Product Overview‌

Oclacitinib Maleate (CAS 1208319-27-0), also known as PF-03394197, is a selective Janus kinase 1 (JAK1) inhibitor widely used in veterinary medicine to treat allergic dermatitis and pruritus in dogs. It modulates cytokine signaling to reduce inflammation and itching, offering rapid symptom relief.

✔️ ‌Key Advantages‌

• ‌High Purity‌: ≥99% HPLC purity compliant with ‌USP/EP‌ standards.

• ‌Bulk Availability‌: Custom batches from 1g to 25kg with COA, MSDS, and stability data.

• ‌Formulation Flexibility‌: White crystalline powder soluble in DMSO (≥20 mg/ml) for oral or topical use.

🏥 ‌Applications‌

• ‌Canine Allergic Dermatitis‌: First-line therapy for controlling itching and skin inflammation.

• ‌Veterinary Pharmaceuticals‌: Key ingredient in commercial antipruritic medications.

• ‌Research‌: Reference standard for JAK1 pathway studies in immunology.

📜 ‌Quality Compliance‌

• Certified under ‌USP/EP‌ guidelines with residual solvents <10ppm and heavy metals <20ppm.

• Stability tested for 24 months at -20°C in airtight, light-resistant packaging.

📈 ‌Market Trends‌

The global veterinary dermatology market is projected to grow at ‌6.5% CAGR (2025-2030)‌, driven by rising demand for targeted therapies like Oclacitinib Maleate. Its selective JAK1 inhibition ensures efficacy with minimal systemic side effects.